{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:39:52Z","timestamp":1787269192162,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.semarthrit.2024.152606","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:59:55Z","timestamp":1733227195000},"page":"152606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis"],"prefix":"10.1016","volume":"70","author":[{"given":"Marco","family":"Binda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Moccaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Salvato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Cuberli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Padoan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Zanatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2024.152606_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0002","first-page":"15","article-title":"Update on systemic sclerosis","author":"McCray","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0003","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/annrheumdis-2019-215787","article-title":"Revised European scleroderma trials and research group activity index is the best predictor of short-term severity accrual","volume":"78","author":"Fasano","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152606_bib0004","first-page":"202","article-title":"Scleroderma (systemic sclerosis): classification, subsets and pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J Rheumatol"},{"issue":"9","key":"10.1016\/j.semarthrit.2024.152606_bib0005","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1002\/art.40906","article-title":"Phenotypes determined by cluster analysis and their survival in the prospective European scleroderma trials and research cohort of patients with systemic sclerosis","volume":"71","author":"Sobanski","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152606_bib0006","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152606_bib0007","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152606_bib0008","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/art.41153","article-title":"Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis","volume":"72","author":"Nihtyanova","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0009","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1016\/S2665-9913(22)00217-X","article-title":"Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort","volume":"4","author":"Elhai","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152606_bib0010","doi-asserted-by":"crossref","first-page":"4786","DOI":"10.1093\/rheumatology\/keac188","article-title":"Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort","volume":"61","author":"Zanatta","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152606_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152606_bib0012","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152606_bib0013","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar3495","article-title":"Frequency of disease-associated and other nuclear autoantibodies in patients of the German network for systemic scleroderma: correlation with characteristic clinical features","volume":"13","author":"Mierau","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0014","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1001\/jama.2015.3656","article-title":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement","volume":"313","author":"Stewart","year":"2015","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152606_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152606_bib0016","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.semarthrit.2020.03.009","article-title":"Pseudotumoral calcinosis in systemic sclerosis: data from systematic literature review and case series from two referral centres","volume":"50","author":"Zanatta","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0017","unstructured":"Wells G.A., Shea B., O\u2019Connell D., et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Clin Epidemiol 2013. Available at: https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp (accessed 12.04.24)."},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152606_bib0018","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152606_bib0019","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/diagnostics12051067","article-title":"Autoantibodies versus skin fibrosis extent in systemic sclerosis: a case-control study of inverted phenotypes","volume":"12","author":"Tieu","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"Suppl 125(3)","key":"10.1016\/j.semarthrit.2024.152606_bib0020","first-page":"106","article-title":"Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement","volume":"38","author":"Iniesta Arandia","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0021","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Thinking outside the box\u2014The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.semarthrit.2024.152606_bib0022","doi-asserted-by":"crossref","first-page":"I26","DOI":"10.1093\/rap\/rkad010","article-title":"Clinical phenotype in scleroderma patients based on autoantibodies","volume":"7","author":"Santos","year":"2023","journal-title":"Rheumatol Adv Pract"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0023","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1045523","article-title":"Comprehensive autoantibody profiles in systemic sclerosis: clinical cluster analysis","volume":"13","author":"H\u00f6ppner","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152606_bib0024","doi-asserted-by":"crossref","first-page":"rky002","DOI":"10.1093\/rap\/rky002","article-title":"Distinctive clinical phenotype of anti-centromere antibody-positive diffuse systemic sclerosis","volume":"2","author":"Caetano","year":"2018","journal-title":"Rheumatol Adv Pract"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152606_bib0025","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/rheumatology\/keab850","article-title":"Improvement with time of vascular outcomes in systemic sclerosis: a systematic review and meta-analysis study","volume":"61","author":"Hughes","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0026","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2024.152606_bib0027","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/kew298","article-title":"Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study","volume":"55","author":"Kranenburg","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0028","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3899\/jrheum.201594","article-title":"Systematic analysis of the literature in search of defining systemic sclerosis subsets","volume":"48","author":"Nevskaya","year":"2021","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0029","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/annrheumdis-2022-eular.2123","article-title":"POS0873. Persistent inflammation in systemic sclerosis is strongly associated with severe disease and mortality: an analysis from the EUSTAR database","volume":"81","author":"Sarbu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2024.152606_bib0030","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1183\/09031936.00091212","article-title":"High prevalence of occult left heart disease in scleroderma-pulmonary hypertension","volume":"42","author":"Fox","year":"2013","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152606_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102452","article-title":"Outcomes of limited cutaneous systemic sclerosis patients: results on more than 12,000 patients from the EUSTAR database","volume":"19","author":"Frantz","year":"2020","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152606_bib0032","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3899\/jrheum.181173","article-title":"Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis","volume":"47","author":"de Vries-Bouwstra","year":"2020","journal-title":"J Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224002464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T16:54:07Z","timestamp":1736182447000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224002464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":32,"alternative-id":["S0049017224002464"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152606","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenotype of diffuse cutaneous systemic sclerosis patients with positive anticentromere antibodies: A systematic literature review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152606"}}